CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


assessment of the sequelae after hospitalization for Sars-COV-2Wiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)


Name (Synonyms) Correlation
drug1153 INOpulse Wiki 1.00
drug1822 Placebo Wiki 0.06

Correlated MeSH Terms (2)


Name (Synonyms) Correlation
D045169 Severe Acute Respiratory Syndrome NIH 0.05
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 REassessement After Hospitalization for Sars-COV-2 Infection : Standardized Assessment of Sequelae and Comorbidities 3 to 6 Months After Hospitalization

Currently, the sequelae and short-term medical and psychological impact of the sars-cov-2 infection ("CoVID-19") remain poorly described. The clinical and functional sequelae that may persist after acute sars-cov-2 ("CoVID-19") infection are essential to explore, in order to ensure the best possible follow-up of patients after discharge from hospital.

NCT04443257 Sars-CoV2 Other: assessment of the sequelae after hospitalization for Sars-COV-2

Primary Outcomes

Measure: Development or worsening of a ventilatory disorder and/or chronic respiratory failure assessed by spirometry

Time: 3 to 6 months after Sars coV 2 infection

Secondary Outcomes

Description: assessed by 0-10 Borg scale

Measure: Assessment of dyspnea

Time: 3 to 6 months after Sars coV 2 infection

Description: assessed by lung CT scan

Measure: Description of pulmonary lesions as assessed by lung CT scan

Time: 3 to 6 months after Sars coV 2 infection

Description: assessed by lung CT scan

Measure: Development of pulmonary fibrosis as assessed by lung CT scan

Time: 3 to 6 months after Sars coV 2 infection

Description: assessed by incidence of cardiovascular events, venous thromboembolism, and transthoracic echocardiogram

Measure: Incidence or worsening of cardiovascular diseases

Time: 3 to 6 months after Sars coV 2 infection

Description: renal function and urinary parameters

Measure: Incidence or worsening of renal disease

Time: 3 to 6 months after Sars coV 2 infection

Description: hepatic blood parameters

Measure: Incidence or worsening of liver disease

Time: 3 to 6 months after Sars coV 2 infection

Description: assessed by validated scale: Generalized Anxiety Disorder-7 (GAD7)

Measure: Incidence or worsening of psychological pathology : anxiety

Time: 3 to 6 months after Sars coV 2 infection

Description: assessed by validated scales: Patient Health Questionnaire-9 (PHQ9)

Measure: Incidence or worsening of psychological pathology: depression

Time: 3 to 6 months after Sars coV 2 infection

Description: assessed by validated scale : Post-traumatic Checklist for DSM-5 (PCL-5)

Measure: Incidence or worsening of psychological pathology: post-traumatic stress

Time: 3 to 6 months after Sars coV 2 infection

Description: assessed by validated scale : insomnia severity index (ISI)

Measure: Incidence or worsening of psychological pathology: insomnia

Time: 3 to 6 months after Sars coV 2 infection

Description: assessed by validated scale (EQ-5D-L questionnaire)

Measure: Assessment of the health-related quality of life

Time: 3 to 6 months after Sars coV 2 infection

Description: assessed by the fatigue severity sale

Measure: Assessment of the fatigue

Time: 3 to 6 months after Sars coV 2 infection

Description: assessed by the Evaluation of Deprivation and Inequalities in Health Examination (EPICES) scale

Measure: Assessment of the socioeconomic deprivation

Time: 3 to 6 months after Sars coV 2 infection

Description: assessed by blood glucose level, HbA1C, lipid blood tests, TSH, T3, T4, antithyroperoxydase antibodies, cortisol, ACTH, renin, aldosteron, albumin level, vitamin D level, iron status, weight changes

Measure: development or worsening of metabolic disorders: diabetes, thyroid diseases, dyslipidemia, adrenal disorders, malnutrition

Time: 3 to 6 months after Sars coV 2 infection

Description: assessed by lupus anticoagulant, anti-cardiolipin, anti-β2-glycoprotein

Measure: Development of auto-immune disorders

Time: 3 to 6 months after Sars coV 2 infection

Description: Presence and levels of anti-SARS-CoV-2 antibodies of IgG, IgA and IgM isotypes

Measure: Assessment of the evolution of the humoral anti-SARS-CoV-2 immunization profile

Time: 3 to 6 months after Sars coV 2 infection

Description: assessed by the International Physical Activity Questionnaire (IPAQ)

Measure: Patients' self-reported level of physical activity

Time: 3 to 6 months after Sars coV 2 infection

Measure: Determination of risk factors associated with sequelae or comorbidities

Time: 3 to 6 months after Sars coV 2 infection


No related HPO nodes (Using clinical trials)